Results 31 to 40 of about 12,086 (172)

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis

BMC Neurology, 2021
Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke but their relative effectiveness and harms still need to be clarified.
Cinzia Del Giovane, Giorgio B. Boncoraglio, Lorenza Bertù, Rita Banzi, Irene Tramacere   +4 more
doaj   +1 more source

Anticoagulant versus antiplatelet therapy for acute ischemic stroke [PDF]

, 2008
Acute ischaemic stroke is a leading cause of death in Canada and should be a priority in health care. This paper defines acute ischaemic stroke and provides current statistics, economic costs, risk factors, treatments, and management options.

core   +1 more source

Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.

PLoS ONE, 2019
Background and purposeThe ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008.
Han-Gil Jeong, Jae Sun Yoon, Juneyoung Lee, Hee-Joon Bae   +3 more
doaj   +1 more source

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Is clopidogrel superior to aspirin in secondary prevention of vascular disease?

Current Controlled Trials in Cardiovascular Medicine, 2000
The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel, ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events trial ...
Algra Ale, van Gijn Jan
doaj   +1 more source

Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. [PDF]

, 2015
BACKGROUND: Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths.
A Kumar, B Heeg, B Sigvant, CW Hamm, CW Hamm, DJ Crespin, F Werf van de, J Latour-Pérez, JL Mega, JL Mega, K Smolina, KA Fox, L Wallentin, M Rosvall, O Ghatnekar, PG Steg, PW Sullivan, R Ara, S Yusuf, SD Wiviott   +19 more
core   +3 more sources

The importance of early diagnosis and treatment of kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon

Dermatology Practical & Conceptual, 2015
Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that may be complicated by Kasabach-Merritt phenomenon (KMP), a profound thrombocytopenia resulting from platelet trapping within a vascular tumor, either KHE or tufted angioma (
Grecia V. Vivas-Colmenares, Gema L. Ramirez-Villar, Jose A. Matute de Cardenas, Jose Bernabeu-Wittel, Israel Fernandez-Pineda   +4 more
doaj   +1 more source

Medical Adjuvant Therapy in Reducing Thrombosis With Arteriovenous Grafts and Fistulae Use: A Meta-Analysis of Randomized Controlled Trials

Clinical and Applied Thrombosis/Hemostasis, 2021
Hemodialysis is required for patients with end-stage renal disease (ESRD) that require arteriovenous (AV) grafts or fistulas for vascular access. These access points are prone to thrombosis. To determine the effect of medical adjuvant therapy on AV graft/
Kaleem Ullah MBBS, Maham Bashir MBBS, Noor Ul Ain MBBS, Azza Sarfraz MBBS, Zouina Sarfraz MBBS, Muzna Sarfraz MBBS, Ivan Cherrez-Ojeda MD, MSc   +6 more
doaj   +1 more source

Dataset of endo- and xenobiotic inhibition of CYP2B6: Comparison to CYP3A4

Data in Brief, 2022
Cytochrome P450 2B6 (CYP2B6) is a human enzyme important in chemical detoxification, steroid and fatty acid metabolism that is primarily hepatic. Therefore, induction or inhibition of CYP2B6 may perturb endo- and xenobiotic metabolism and cause adverse ...
Emily M. Olack, Melissa M. Heintz, William S. Baldwin   +2 more
doaj   +1 more source